BBIO BridgeBio Pharma Inc.

18.62
+0.5  (+3%)
Previous Close 18.12
Open 18.12
Price To Book -6.87
Market Cap 2,173,987,633
Shares 116,755,512
Volume 180,564
Short Ratio
Av. Daily Volume 282,859
Stock charts supplied by TradingView

NewsSee all news

  1. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  2. Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

    PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2021.
AG10 / BBP-265 - ATTRibute-CM
ATTR-CM
Phase 3 trial planned for 2H 2019.
AG10 / BBP-265
ATTR-PN
Phase 2 data to be presented at AHA November 16, 2019, 5:30 PM ET.
AG10 / BBP-265 - open label
ATTR-CM
Phase 3 enrolment to commence 2019.
BBP-831
Cholangiocarcinoma
Phase 3 trial to commence 2020.
BBP-831
Urothelial carcinoma
Phase 3 trial to conclude 2020.
BBP-009
Gorlin syndrome
Phase 2b trial to commence in 2019.
BBP-009
High-Frequency Basal Cell Carcinoma
Rolling NDA to be filed in 2019.
BBP-870
Molybdenum cofactor deficiency type A
Phase 1/2 data due 2020.
BBP-589
Epidermolysis bullosa

Latest News

  1. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  2. Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

    PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,